Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast


Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments

SAN DIEGO, July 24, 2025 /PRNewswire/ -- In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between life and death. But with the rise of counterfeit medications and drug combinations that are more potent and less predictable, emergency departments must adapt faster than ever.

Vonda McAllister, Director of Global Product Management, QuidelOrtho.

QuidelOrtho Science Bytes Episode 49 "How Urgent Diagnostic Testing Can Help Prevent Drug Overdose Deaths," addresses the escalating complexities of substance use detection and care in emergency departments across the country. The episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho, whose deep experience in diagnostics and toxicology provides critical perspective on the clinical and societal impacts of today's most dangerous drug trends.

Subscribe to QuidelOrtho Science Bytes

Episode Highlights:

  • How rapid diagnostic testing is saving lives
  • Understanding the unpredictable nature of polydrug overdoses
  • The increasing prevalence of potent synthetic drugs like fentanyl, xylazine ("tranq"), and nitazines
  • The limitations of Narcan (naloxone) and the rising need for repeated doses due to powerful opioid analogs
  • California's "Tyler's Law," which mandates fentanyl testing in suspected overdose cases

Key Quotes:

Vonda McCallister, Director of Global Product Management, QuidelOrtho

"As overdose presentations become more complex, continuous monitoring, comprehensive toxicology screening and clinical vigilance are essential tools in the fight against this crisis."

About QuidelOrtho Science Bytes

Science Bytes is a monthly podcast that delivers diagnostic insights and innovation updates from QuidelOrtho, helping healthcare providers stay informed and prepared. Episode 49 is now available on all major podcast platforms.

For more information and to listen to the full episode, visit www.quidelortho.com/sciencebytes.

About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of innovative diagnostic testing solutions. From infectious diseases to cardiac biomarkers to women's health, QuidelOrtho transforms the power of diagnostics into a healthier future through science, innovation, and accessibility. Learn more at www.quidelortho.com.

Source: QuidelOrtho Corporation

Investor Contact:

Juliet Cunningham

Vice President, Investor Relations

IR@QuidelOrtho.com

 

Media Contact:

D. Nikki Wheeler

Senior Director, Corporate Communications

Media@QuidelOrtho.com

 

 

QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/urgent-need-for-early-detection-in-drug-overdose-cases-highlighted-in-new-podcast-302512078.html

SOURCE QuidelOrtho Corporation

Werbung

Quidel Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quidel nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
22.01.18 Quidel Overweight Barclays Capital
18.07.17 Quidel Buy Canaccord Adams
25.04.17 Quidel Hold Canaccord Adams
08.01.16 Quidel Buy Canaccord Adams
02.09.15 Quidel Overweight Barclays Capital

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.